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A B S T R A C T
The use of next generation sequencing has the power to expedite the identiﬁcation of drug resistance
determinants and biomarkers and was applied successfully to drug resistance studies in Leishmania. This
allowed the identiﬁcation of modulation in gene expression, gene dosage alterations, changes in chro-
mosome copy numbers and single nucleotide polymorphisms that correlated with resistance in Leishmania
strains derived from the laboratory and from the ﬁeld. An impressive heterogeneity at the population
level was also observed, individual clones within populations often differing in both genotypes and phe-
notypes, hence complicating the elucidation of resistance mechanisms. This review summarizes the most
recent highlights that whole genome sequencing brought to our understanding of Leishmania drug re-
sistance and likely new directions.
© 2014 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
3.0/).
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1. The parasite Leishmania and chemotherapy
Leishmania are digenetic parasites that develop as promastigotes
in the gut of phlebotomine sandﬂies and as intracellular amastigotes
in themacrophages of vertebrate hosts. The Leishmania genus gathers
together several species and can be further subdivided into two
subgenera (the subgenus Leishmania Viannia and the subgenus Leish-
mania Leishmania) based on the localization of promastigotes in the
alimentary tract of the insect. The species L. donovani and L. infantum
(also referred to as L. chagasi in South America) are mainly respon-
sible for visceral leishmaniasis, a condition that manifests as a gross
inﬂammatory reaction within the viscera (spleen and liver) that is
fatal if left untreated. On the other hand, the etiology of cutane-
ous leishmaniasis is much more diverse and manifests as self-
healing skin ulcers or nodules that remain localized at the site of
inoculation or metastasize to remote body sites (Reithinger et al.,
2007). A more severe complication called muco-cutaneous leish-
maniasis involving the destruction of the nasal mucosa can also
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happen and is most commonly associated with L. Viannia braziliensis
in South America. Globally, 1–1.5 million new cases of leishmani-
asis are estimated to occur each year with a case-fatality rate of 10%
for the visceral form of the disease (Alvar et al., 2012).
There is not yet an effective vaccine registered against Leishma-
nia but the immune protection observed upon healing of cutaneous
leishmaniasis suggests that designing an effective vaccine should
be achievable (reviewed in (Palatnik-de-Sousa, 2008)). Mean-
while, the control of leishmaniasis primarily relies on chemotherapy
with only a limited number of registered molecules available. Pen-
tavalent antimonials (either as sodium stibogluconate, meglumine
antimoniate or generic formulations) have been the standard drug
for more than 60 years and remain the primary line of treatment
in many endemic regions, apart from Nepal and the Bihar state of
India where antimonial formulations have been rendered almost
obsolete due to widespread parasite resistance (Lira et al., 1999;
Sundar et al., 2000; Rijal et al., 2003). Other recommended thera-
pies include the polyene antibiotic amphotericin B for which a single-
dose was shown to be 95% effective against visceral leishmaniasis
in India (Sundar et al., 2010). Liposomal amphotericin B has become
a standard treatment in many countries (Bern et al., 2006) but
remains expensive even for single-course treatments (Meheus et
al., 2010) and requires administration by intravenous route. There
have been extensive efforts to develop new AmB formulations to
replace the costly lipid-based formulations but no nonlipid-based
AmB delivery systems have yet reached the clinic (Mohamed-Ahmed
et al., 2012). Geographical differences in response rates to lipo-
somal amphotericin Bwere also reported, with visceral leishmaniasis
cases in India being more responsive than those from East Africa
or South America (Berman et al., 1998). The alkyl-lysophospholipid
analogmiltefosine, a drug initially developed as an anti-tumoral com-
pound, is the ﬁrst effective oral drug against Leishmania (Croft et
al., 1987; Jha et al., 1999). It has been successfully used for the treat-
ment of visceral leishmaniasis since its registration in 2002 in India
(Sundar et al., 2002) and was incorporated into the visceral leish-
maniasis elimination programme for the Indian sub-continent.
However, relapse rates of 20% recently observed in Nepal at 12
months post-treatment constitute an alarming signal and empha-
size the need for careful monitoring (Rijal et al., 2013). Miltefosine
might also be effective against cutaneous leishmaniasis, although
regional differences in susceptibility were reported in South America
(Soto et al., 2001, 2004, 2008; Gonzalez et al., 2009). The
aminoglycoside paromomycin is the molecule the most recently ap-
proved for the treatment of visceral leishmaniasis. It was shown to
have anti-leishmanial properties more than ﬁfty years ago but it is
only in the late 1990s that the eﬃcacy of a parenteral formulation
against visceral leishmaniasis was demonstrated by a phase III clin-
ical trial, leading to registration for treatment of visceral leishmaniasis
in India in 2006 (Jha et al., 1998; Sundar et al., 2007). Similarly to
amphotericin B and miltefosine however, geographical variations
also occur for the eﬃcacy of paromomycin against visceral leish-
maniasis as it appears to be less effective as monotherapy in East
Africa (especially Sudan) than in India for a reason not yet under-
stood (Hailu et al., 2010; Musa et al., 2010).
Drug combination is an established approach for the treat-
ment of several infectious diseases (e.g. malaria, HIV-1 and
tuberculosis) and is starting to be considered for the treatment of
tropical diseases like visceral leishmaniasis. The appeal for the de-
velopment of combination therapies is two-fold: to reduce the length
of treatment in order to improve compliance (e.g. the miltefosine
regimen involves a 4 weeks, twice daily drug intake), and to delay
the emergence of resistance to protect the few molecules avail-
able. Nonetheless, there is still a risk that parasites could develop
resistance to combination of drugs, being of particular impor-
tance those ones involving paromomycin as shown for L. donovani
(Garcia-Hernandez et al., 2012). Several attempts to combine drugs
have been made for the treatment of visceral leishmaniasis but as
this falls outside the scope of this review the reader is referred to
two recent reviews on the topic (Olliaro, 2010; van Griensven et al.,
2010).
In this review, wewill summarize themost recent highlights that
next generation sequencing (NGS) brought to our understanding of
drug resistance in the parasite Leishmania.
2. Next-generation sequencing technologies
NGS sequencing platforms have becomewidely available in recent
years with associated costs now being orders of magnitude lower
than classic Sanger sequencing. Different NGS platforms have reached
the market during the past decade, including Illumina, Roche’s 454
pyrosequencing, Life Technologies’ Ion Torrent (PGM/Proton), Applied
BioSystems’ SOLiD System, and Paciﬁc Biosciences’ PacBio sequenc-
ing system. Each platform has speciﬁc advantages and disadvantages
and it is important to carefully ﬁgure out which instrument is best
suited to a given laboratory’s needs in terms of reads accuracy, reads
length, throughput and cost. A thorough description of the differ-
ent sequencing technologies is available in (Liu et al., 2012; Bahassi
and Stambrook, 2014; Buermans and den Dunnen, 2014; van Dijk
et al., 2014), for which the main highlights are summarized here.
For a long time, the main advantage of 454 pyrosequencing was the
long read lengths of 500–1000 bases produced in relatively fast run
times. However, this technology suffers from low throughput, high
cost and high error rates in homopolymer repeats. Owing to the ever
increasing read lengths from competitor platforms, this technolo-
gy has now become less cost eﬃcient and will phase out in mid-
2016. SOLiD sequencing provides high throughput and very high
read accuracy, owing to the fact that each base is read twice during
sequencing, but suffers from short read lengths and relatively long
run times. Illumina has emerged as the leader in the ﬁeld of NGS
and is now offering the highest throughput and the lowest per-
base cost. The read length of up to 300 bases also makes this
technology compatible with most applications. This is the NGS plat-
form that has been used for producing most of the Leishmania
genome reported in the literature to date. The semi-conductor tech-
nology of Life Technologies’ PGM/Proton platforms beneﬁts from
fast run times because it does not rely on optical scanning of ﬂu-
orescent nucleotides for sequencing. The PGM/Proton technology
also generates reads whose lengths are compatible with most ap-
plications but suffers from high error rates in homopolymer repeats.
For now, the sequence yield per run is less than that of Illumina’s
HiSeq systems but the PGM/Proton’s platform is evolving at a very
rapid pace.
Themain advantage of the PacBio system compared to other plat-
forms consists in the long reads that it generates (i.e. up to 20 kb
and even longer). The PacBio system also enables to sequence in-
dividual templatemolecules, in contrast to the other platformswhich
are not sensitive enough to detect the extension of single nucleo-
tide at the level of individualmolecules and thus require a local clonal
ampliﬁcation of the initial template to increase the signal-to-
noise ratio. PacBio sequencing suffers from high cost, high error rates
and low throughput however and is thus suitable to a limited range
of applications like increasing the quality of de novo genome as-
semblies. Indeed, owing to their small read length, typical NGS
platforms are very sensitive to the presence of DNA repeats but com-
bining high-quality short reads (either derived from Illumina or PGM/
Proton platforms) with long (less accurate) PacBio reads now enables
the reconstruction of long error-free reads that crosses many more
DNA repeats and missing bases for producing very-high quality
genome assemblies (Koren et al., 2012). This should prove espe-
cially useful for decreasing the number of gaps from genome
assemblies for which DNA repeats abound as in the case of Leish-
mania (Ubeda et al., 2014) and for detecting chromosome
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rearrangements. In our experience, PacBio sequencing successful-
ly reduced the number of L. infantum contigs by one order of
magnitude, from 2000 contigs for paired-end Illumina sequencing
alone to less than 175 contigs when including PacBio sequencing
(N50 723,631 bp).
The road from raw sequence data to ﬁnal results involves a
number of analytical steps. A generalised analysis pipeline for NGS
data includes processing the reads to remove adapter sequences and
low-quality reads, aligning the reads to a known reference genome
and/or reconstructing genome sequence by de novo assembly.
Several free software packages are available to facilitate NGS data
analysis, ranging from alignment tools like MAQ (Li et al., 2008a),
BWA (Li and Durbin, 2009), Bowtie2 (Langmead and Salzberg, 2012),
SOAP (Li et al., 2008b), SSAHA2 (Ning et al., 2001) and SMALT
(www.sanger.ac.uk/resources/software/smalt/) to de novo assembler
like Velvet (Zerbino and Birney, 2008), Ray (Boisvert et al., 2010),
ALLPATHS-LG (Gnerre et al., 2011), SOAPdenovo2 (Luo et al., 2012),
SGA (Simpson and Durbin, 2012) and ABySS (Simpson et al., 2009).
Owing to the numerous tools available, selecting the software
suitable for speciﬁc applications is not trivial and the reader is
referred to studies that conducted comparison of the performance
of major software for alignment (Fonseca et al., 2012) and de novo
assembly (Salzberg et al., 2012). A comprehensive list of the tools
available for the analysis of NGS data has been produced (Henry et
al., 2014) and can be accessed through the OMIC tools portal
(www.omictools.com). Finally, the Broad Institute’s Genome Analysis
Toolkit provides a structured programming framework that offers
a wide variety of tools for analyzing next-generation re-sequencing
data, with a primary focus on the discovery of high quality variant
sites (McKenna et al., 2010; DePristo et al., 2011).
3. The Leishmania genomes
Several high-quality draft or ﬁnished genomes are available for
Leishmania species conferring visceral diseases (L. infantum JPCM5
and L. donovani BPK282/0cl4) (Peacock et al., 2007; Downing et al.,
2011), cutaneous diseases (L. major Friedlin, L. mexicana U1103)
(Ivens et al., 2005; Rogers et al., 2011) or muco-cutaneous dis-
eases (L. braziliensis M2904) (Peacock et al., 2007). The genomes of
L. tarentolae (Raymond et al., 2012) and of L. amazonensis (Real et
al., 2013) have also been produced. The genomes of L. infantum, L.
donovani, L. major and L. tarentolae each consist of 36 chromo-
somes (Ivens et al., 2005; Peacock et al., 2007; Downing et al., 2011;
Raymond et al., 2012). On the other hand, the genome of L. braziliensis
contains 35 chromosomes due to a fusion event between chromo-
somes 20 and 34 (Britto et al., 1998; Peacock et al., 2007), while
the genome of L. mexicana consists of 34 chromosomes owing to
two fusions events between chromosomes 8 and 29 and chromo-
somes 20 and 36 (Britto et al., 1998; Rogers et al., 2011). Draft
genomes have also been produced for a number of other Leishma-
nia species and these are available at TriTrypDB (www.trytripdb.org).
Globally, the genomes are characterized by a high degree of
synteny between species despite an estimated 20–100million years
of separation between the L. Viannia spp. and the L. Leishmania spp.
(Peacock et al., 2007). Comparative genomics also revealed a re-
markably small number of species-speciﬁc genes, with less than
twenty genes or paralogous groups speciﬁc to either L. infantum,
L. major or L. mexicana (Britto et al., 1998; Rogers et al., 2011). The
number of unique paralogous groups is slightly higher for L.
braziliensis (67 genes) and L. tarentolae (95 genes), which is con-
sistent with their outlier classiﬁcation in the Viannia subgenus and
the SauroLeishmania subgenus (which exclusively parasitize lizards),
respectively. Moreover, L. tarentolae lacks genes associated with the
intracellular life stage of pathogenic species (Raymond et al., 2012)
and L. braziliensis holds features absent from Leishmania Leishma-
nia ssp. such as functional RNA interference machinery as well as
transposable elements (Peacock et al., 2007; Lye et al., 2010). This
scarcity of species-speciﬁc genes suggests that disease tropism and
variations in drug susceptibility between species are likely to involve
differences in gene expression and gene dosage of common core
genes, as previously shown for miltefosine for which the level of
expression of the transporter responsible for miltefosine intake cor-
related with intrinsic variations in susceptibility between Leishmania
species (Yardley et al., 2005; Sanchez-Canete et al., 2009).
Leishmania parasites have a peculiar mechanism of gene expres-
sion. Protein-coding genes are distributed on chromosomes as part
of contiguous units on the same DNA strand and are co-transcribed
as polycistronic transcription units by RNA-polymerase II before
primary transcripts are matured into messenger RNAs (mRNA) by
trans-splicing for the addition of a 39 nucleotides splice leader cap
and poly-A tail (reviewed in (Haile and Papadopoulou, 2007)). Tran-
scription initiation is bidirectional and takes place at strand-
switch regions separating divergent transcriptional units
(Martinez-Calvillo et al., 2003; Thomas et al., 2009). Conversely, tran-
scription terminates at the level of strand-switch regions speciﬁed
by convergent transcriptional units (Martinez-Calvillo et al., 2004).
In the absence of promoters for regulating gene expression, the level
of mRNA is controlled by RNA stability rather than by increased RNA
polymerase activity (Muller et al., 2010a, b). To adapt to stressful
environments (including drug pressure) in the absence of tran-
scriptional control, Leishmania has evolved mechanisms to alter
mRNA levels that include increased gene dosage through gene am-
pliﬁcation (Ubeda et al., 2008; Leprohon et al., 2009b) or duplication
(Mukherjee et al., 2011), gene deletion (Ouameur et al., 2008) and
aneuploidy (Ubeda et al., 2008; Leprohon et al., 2009b). Converse-
ly, single nucleotide polymorphisms in drug targets or key enzymes
(Ritt et al., 2013) or transporters (Perez-Victoria et al., 2003; Coelho
et al., 2012) can also favor adaptation without the need for alter-
ing gene expression.
4. Gene copy numbers
Copy number variations either through gene ampliﬁcation or gene
expansion enable generating substantial genome variability and
Leishmania cells selected for resistance to cytotoxic compounds often
amplify or delete a number of speciﬁc loci coding for either drug
targets or drug transporters (reviewed in (Beverley, 1991; Ouellette
and Papadopoulou, 1993)). The ﬁrst example of gene ampliﬁca-
tion was the DHFR-TS gene in methotrexate resistant Leishmania
(Coderre et al., 1983) but several locus have been found ampliﬁed
after selection with a number of drugs (Ouellette and Papadopoulou,
1993). Ampliﬁed DNAs are generally extrachromosomal and found
either as circular elements (Beverley et al., 1984; Garvey and Santi,
1986; Petrillo-Peixoto and Beverley, 1988; White et al., 1988) or as
linear minichromosomes (Beverley and Coburn, 1990; Tripp et al.,
1991; Papadopoulou et al., 1993; Navarro et al., 1994; Olmo et al.,
1995; Grondin et al., 1998). While circles are formed by homolo-
gous recombination between direct repeated sequences (Ouellette
et al., 1991; Grondin et al., 1993; Ubeda et al., 2008; Leprohon et
al., 2009b), minichromosomes are generated by annealing of in-
verted repeats which lead to palindrome formation (Navarro et al.,
1994; Olmo et al., 1995; Dubessay et al., 2001; Ubeda et al., 2008).
Repeated sequences used for DNA ampliﬁcation are generally non-
coding and are highly conserved between different Leishmania species
(Ubeda et al., 2008). Interestingly, a recent bioinformatics analysis
revealed that such sequences are widespread in the Leishmania
genomes and that most of the Leishmania genome is stochasti-
cally subjected to gene rearrangements at the level of these low-
copy repeated sequences (Ubeda et al., 2014). Cells in the population
are having a common core genome but differ in their extrachro-
mosomal amplicon complement. This translates into an extensive
heterogeneity at the population level and introduces phenotypic
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leaps that were shown to foster the selection of adaptive traits in
response to drug pressure (Ubeda et al., 2014).
Gene ampliﬁcation was ﬁrst observed by comparison of di-
gested genomic DNAs of sensitive and resistant parasites migrated
on agarose gels and stained with ethidium bromide. The complex-
ity of the DNA is low enough that it is possible to detect a 5–10 fold
increase in gene copy (Ouellette et al., 1998). More recently, DNA
microarrays have also allowed the detection of gene ampliﬁcation
given the strong correlation between RNA abundance and gene copy
number (Guimond et al., 2003; Ubeda et al., 2008; Leprohon et al.,
2009b; do Monte-Neto et al., 2011; Kumar et al., 2013). Now, as-
sessing read depth coverage from whole genome sequencing data
allows the precise mapping of ampliﬁed genomic loci and assists
in the identiﬁcation of repeated regions involved in homologous re-
combination. A recent analysis of the genome sequence of seventeen
L. donovani ﬁeld isolates from the Indian subcontinent identiﬁed gene
copy number variations that could discriminate isolates according
to their susceptibility to sodium stibogluconate (SSG) (Downing et
al., 2011). Among these, a four-gene extrachromosomal circular
amplicon coding for amitogen-activated protein kinase derived from
chromosome 36 was detected in signiﬁcantly higher copies in SSG-
resistant than in SSG-sensitive isolates. This difference in amplicon
counts was stable as it was preserved despite the thirty in vitro pas-
sages between the collection of isolates and DNA extraction
(Downing et al., 2011). While its role in antimony resistance remains
to be functionally conﬁrmed, the abundance of the four-gene
amplicon could be used as a biomarker for the detection of anti-
mony resistance in the event that its distribution proves to be
widespread among SSG-resistant isolates. Amplicons derived from
the H locus harboring the ABC gene MRPA were also observed in
the L. donovani lines but in similar amounts between the SSG-
resistant and SSG-sensitive isolates. Amplicons generated from the
H locus were previously found not to be stable in the absence of
drug pressure however (Leprohon et al., 2009b) and the lack of cor-
relation with resistance might thus come from the culturing of
isolates prior to DNA extraction (Downing et al., 2011). Interest-
ingly, a locus previously reported to be ampliﬁed in L. tarentolae
selected for resistance to SSG and whose abundance correlated with
the level of SSG resistance (Haimeur and Ouellette, 1998) was present
in more copies in the L. donovani SSG-resistant lines (Downing et
al., 2011).
In addition to extrachromosomal gene ampliﬁcation, altered gene
dosage can also occur by gene duplication or gene deletion. Tandem
gene arrays have been identiﬁed in every Leishmania species
analysed. Interestingly, a third of these multicopy genes are species-
speciﬁc and increased gene dosage arising from such tandem
duplication may thus allow variations in transcript levels for some
genes deﬁning important species-speciﬁc features (Rogers et al.,
2011). Most of the tandem arrays that are unique to each species
are hypothetical proteins however and further investigation is
warranted to examine these hypothetical genes for their role
in the biology of Leishmania parasites (Rogers et al., 2011).
Intrachromosomal segmental ampliﬁcation through rearrange-
ments at the level of direct repeats can also occur while attempting
gene knockouts as shown for the subtelomeric essential gene gsh1
encoding gamma-glutamylcysteine synthetase, the rate limiting step
in the biosynthesis of glutathione in Leishmania (Mukherjee et al.,
2011). Chromosomal repeat expansion enabled the parasites to cir-
cumvent the sequential rounds of gene inactivation by becoming
polyploid for the gsh1 locus (Mukherjee et al., 2011). Interest-
ingly, intrachromosomal rearrangements leading to altered gene
dosage were also observed in the context of antimony resistance
in a series of L. major laboratory-derived mutants (Mukherjee et al.,
2013). Read depth coverage from next generation sequencing data
revealed that while chromosome 31 was at least hexasomic in every
strain including wild-type cells, a subtelomeric region was deleted
for at least four of the chromosome 31 alleles in all mutants
(Mukherjee et al., 2013). The breaks mostly occurred at the level
of inverted repeated sequences and differed betweenmutants. Most
interestingly, careful analysis of sequencing reads revealed an even
more heterogeneous proﬁle at the population level where two of
the three mutants were found to include subpopulations of para-
sites with different breakpoints for the terminal deletion of
chromosome 31 (Mukherjee et al., 2013). The deleted region har-
bored the gene coding for the aquaglyceroporin AQP1 which is
responsible for the uptake of trivalent antimony in Leishmania
(Gourbal et al., 2004). Decreasing the number of AQP1 copies reduces
trivalent antimony entry (Gourbal et al., 2004) and confers resis-
tance (Gourbal et al., 2004; Marquis et al., 2005). In addition to AQP1
deletions, a subtelomeric ampliﬁcation of part of chromosome 34
was also deduced from the sequencing reads in one of the L. major
antimony-resistant mutants (Mukherjee et al., 2013). While an in-
crease in copy number of a segment close to a telomere is often
indicative of a linear amplicons (Ubeda et al., 2008), the chromo-
some proﬁle on pulse ﬁeld gel electrophoresis correlated instead
with a complex intrachromosomal rearrangement (Mukherjee et al.,
2013). Two genes on the ampliﬁed locus, encoding an ascorbate-
dependent peroxidase and a putative glucose-6-phosphate
dehydrogenase, were further linked with antimony resistance. Both
genes are central to the redox defence in Leishmania and their in-
creased dosage was shown to protect parasites against the reactive
oxygen species that antimony is known to induce (Mehta and Shaha,
2006; Moreira et al., 2011; Mukherjee et al., 2013).
5. Chromosome copy numbers
Another layer of complexity for altering gene dosage can be found
at the level of whole chromosome copy numbers. Additional chro-
mosome copies are known to occur in various Leishmania species
when attempting to knockout essential genes (Cruz et al., 1993;
Mottram et al., 1996; Dumas et al., 1997; Martinez-Calvillo et al.,
2005). In recent years, assessment of read depth coverage from next-
generation sequencing data from reference Leishmania genomes has
shown the presence of supernumerary chromosomes in every species
analysed and conﬁrmed that aneuploidy is much more wide-
spread in Leishmania than initially anticipated, being common even
in cells not submitted to any stress besides culturing (Rogers et al.,
2011). The extent of aneuploidy varies between species or strains,
and L. infantum/L. donovani appears to be the most aneuploid at the
population level (Downing et al., 2011; Rogers et al., 2011). Also,
an astonishing small number of chromosomes appear to be disomic
in all species of the Leishmania subgenus (Downing et al., 2011;
Rogers et al., 2011). Interestingly, the fact that many of these are
enriched for gene arrays suggests that there may be a selection
against whole-chromosome duplication for chromosomes harbor-
ing a higher proportion of putatively dose-sensitive genes in
Leishmania species (Rogers et al., 2011). Chromosome 31, which was
ﬁrst shown to be supernumerary in L. major (Akopyants et al., 2009),
is the only chromosome whose copy number is increased in every
Leishmania species (Downing et al., 2011; Rogers et al., 2011;
Mukherjee et al., 2013), even for the non-pathogenic L. tarentolae
(Raymond et al., 2012). L. braziliensis is distinct from the species be-
longing to the Leishmania subgenus in being trisomic for most
chromosomes (Rogers et al., 2011) but it remains to be seen whether
this is maintained in other species from the Viannia subgenus.
Chromosome copy numbers calculated from read depth cover-
age can sometimes lead to a cumulative ploidy not matching with
a clear-cut number of chromosomes but instead to intermediate
somy values (e.g. median chromosome coverage between disomy
and trisomy). Fluorescence in situ hybridization of single cells ex-
plained this phenomenon by revealing that distinct aneuploidy
patterns also occur at the level of individual cells within a given
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population (Sterkers et al., 2011; Lachaud et al., 2014). Indeed, every
chromosome analysed were show to be present in a least two ploidy
states (one predominant and other minor states) in population of
parasites and, similarly to the stochastic gene ampliﬁcation de-
scribed in section 3, thismosaic aneuploidywas proposed to generate
intra-strain heterogeneity that should ultimately translate into in-
creased adaptability at the population level (Sterkers et al., 2011).
In the context of drug resistance, aneuploidy has ﬁrst been ob-
served while performing comparative gene expression analyses by
DNA microarrays on Leishmania parasites resistant to antimony
(Leprohon et al., 2009b) or methotrexate (Ubeda et al., 2008), and
later in L. major antimony-resistant mutants (Mukherjee et al., 2013)
and in L. donovani selected for resistance to the HIV-1 protease in-
hibitor Nelﬁnavir (Kumar et al., 2013). Increased and decreased
mRNA levels were observed for entire chromosomes and compar-
ative genomic hybridization further conﬁrmed this being related
with the presence of supernumerary chromosomes and chromo-
some loss, respectively. In the case of L. infantum and L. major
mutants resistant to antimony, this was further validated by com-
puting chromosomal read depth coverage from whole genome
sequencing data (Brotherton et al., 2013; Mukherjee et al., 2013).
In all cases tested, withdrawal of drug pressure resulted in partic-
ular supernumerary chromosomes reverting to the somy observed
prior to the induction of resistance, suggesting that aneuploidy can
assist drug resistance (Ubeda et al., 2008; Leprohon et al., 2009b;
Kumar et al., 2013). The levels of mRNA were also consistent with
the altered chromosome stoichiometry but whether a speciﬁc gene
or group of genes on aneuploid chromosomes is responsible for re-
sistance has not been directly addressed, and the link between
aneuploidy and drug resistance thus remains circumstantial. Quan-
titative proteomics by stable isotope labeling of amino acids in cell
culture from the same L. infantum antimony-resistant mutant as in
(Leprohon et al., 2009b) failed to correlate chromosome copy
numbers with protein levels however but this is possible if the bulk
of extra mRNA molecules is not translated (expect for those extra
transcripts implicated in resistance) or if their protein products are
degraded shortly after synthesis, as previously demonstrated in an-
euploid yeast (Torres et al., 2007). Of note, resistance resulting from
whole chromosome aneuploidy in ﬂuconazole-resistant Candida
albicans (Selmecki et al., 2006, 2010) and Crytptococcus neoformans
(Sionov et al., 2010) was attributed to the increased expression of
two speciﬁc genes located on supernumerary chromosome 5
(Selmecki et al., 2006, 2008). Similarly, adaptation of budding yeasts
to the Hsp90 inhibitor radicicol induces duplication of chromo-
some 15 for which the synergistic effect conferred by the increased
dosage of two genes encoding an Hsp90 co-chaperone and a drug
pump on the chromosome was shown to be responsible for most
of the resistance (Chen et al., 2012). Hence, although altered chro-
mosome stoichiometry can lead to expression pattern changes for
many genes, adaptive traits resulting from aneuploidy can be at-
tributed to dosage ﬂuctuations of speciﬁc genes on supernumerary
chromosomes.
Analysis of read depth coverage from whole genome sequenc-
ing data is just beginning to be used for assessing aneuploidy in the
context of drug resistance in natural Leishmania populations. Given
the very high prevalence of antimony resistance in Nepal and India,
the studies described so far mainly focused on antimony resistant
isolates recovered from the Indian subcontinent. The analysis of sev-
enteen L. donovani isolates either sensitive or resistant to SSG
revealed an extensive aneuploidy among the strains (Downing et
al., 2011). Again, few chromosomes were disomic in all samples
(those correlated well with disomic chromosomes from (Rogers et
al., 2011)) and only chromosome 31 was increased in every strain.
Twenty-six chromosomes had varying ploidy across the different
lines. No signiﬁcant pattern of aneuploidy could be associated with
the SSG resistant phenotype however and each isolate had a unique
karyotype. Conversely to the laboratory-derived mutants de-
scribed above, the inﬂuence of chromosomal copy numbers on gene
transcripts levels was not so clear given the poor correlation between
the depths of coverage for cDNA-derived and genomic DNA-
derived sequencing reads (Downing et al., 2011). This analysis was
only performed for one out of the seventeen L. donovani strains
however and might thus have to be tested more widely.
6. Single nucleotide polymorphisms
Besides gene dosage ﬂuctuations, single nucleotide mutations
constitute another strategy to circumvent drug pressure. Point mu-
tations can lead to resistance by interfering with drug-target
interactions (Arrebola et al., 1994) or by altering the permeability
of the cell for the drug (Vasudevan et al., 1998, 2001). While every
antimony resistancemechanisms described so far implicated changes
in gene copy numbers or transcripts levels, whole genome sequenc-
ing is beginning to reveal a role for point mutations in resistance.
The genome sequence of a L. infantum mutant selected in vitro for
resistance to antimony indeed revealed a guanine to adenine tran-
sition at position 1885 of the protein kinase LinJ.33.1810, giving rise
to an E629K substitution in the protein (Brotherton et al., 2013).
Overexpression of the wild-type version of the gene conferred a
modest but reproducible and signiﬁcant sensitization of the mutant,
hence implicating themutation in resistance (Brotherton et al., 2013).
Interestingly, amitogen-activated protein kinase 1was recently found
to be downregulated in L. donovani antimony-resistant ﬁeld iso-
lates and to correlate with resistance (Ashutosh et al., 2012).
Antimony is a known protein phosphatase inhibitor (Pathak and Yi,
2001) and it is possible that mutations (or a decreased expres-
sion) in protein kinases may compensate for the inhibition of
phosphatase activities. In L. guyanensis, the selection of resistance
to antimony was accompanied by a reduced accumulation of the
drug mainly due to genomic alterations at the level of the
subtelomeric region of chromosome 31 harboring the gene coding
for AQP1. For one mutant, the transport defect was correlated with
the presence of a single nucleotide polymorphism at position 398
of AQP1 identiﬁed by whole genome sequencing, leading to the re-
placement of a glycine residue by an aspartic acid at position 133
(G133D) of the protein. The role of this missense mutation in re-
sistance was functionally conﬁrmed by overexpression experiments,
whereby a wild-type AQP1 but not its altered AQP1G133D version was
able to re-sensitize AQP1-null L. guyanensis parasites to antimony
(Monte-Neto, et al., submitted).
Whole genome sequencing also revealed several mechanisms of
resistance to 5-ﬂuorouracil including point mutations while seeking
for further insights into pyrimidine metabolism in Leishmania (Ritt
et al., 2013). 5-ﬂuorouracil is a pyrimidine analog speciﬁcally in-
hibiting thymidilate synthase that displays anti-leishmanial activity
(Katakura et al., 2004). Besides ampliﬁcation of the dhfr-ts target
locus, point mutations in an uridine phosphorybosyl transferase, a
thymidine kinase and an uridine phosphorylase, all linked to py-
rimidine metabolism in kinetoplastids (Hammond and Gutteridge,
1982; Ali et al., 2013), were observed in three independent
laboratory-derived L. infantum 5-ﬂuorouracil resistant mutants (Ritt
et al., 2013). All mutations were further implicated in resistance to
5-ﬂuorouracil by functional experiments. Interestingly, these ex-
periments also highlighted a connection between pyrimidine
metabolism and folate/antifolate metabolism, where a mutation in
thymidine kinase implicated in resistance to 5-ﬂuorouracil also
caused hypersensitivity to methotrexate (Ritt et al., 2013). This could
prove useful for the development of speciﬁc antimetabolites against
Leishmania.
The uptake of miltefosine and other alkyl-glycerophospholipids
in Leishmania is mediated by a P-type ATPase named miltefosine
transporter (MT) which is responsible for the translocation of
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phospholipids from the exoplasmic to the cytoplasmic leaﬂet of the
plasma membrane of the parasite (Perez-Victoria et al., 2003).
Miltefosine uptake further requires a protein named Ros3, the beta-
subunit of the MT (Perez-Victoria et al., 2006). Targeted analyses
of the MT gene in miltefosine-resistant mutants previously re-
vealed that different inactivating mutations are able to drastically
increase resistance to miltefosine (Perez-Victoria et al., 2003). Whole
genome sequencing data from two laboratory-derived L. major
mutants also identiﬁed several distinct MTmutations located at con-
served residues and conferring resistance (Coelho et al., 2012).
Interestingly, the analysis of the MT status in intermediate steps
mutants indicated that mutations in MT are polyclonal, with up to
ﬁve different MT genotypes identiﬁed within a given population. The
number of mutated alleles also correlated with the level of resis-
tance to miltefosine, early selection steps being more heterozygous
for MT point mutations than highly resistant strains which were pri-
marily homozygous for the mutations (Coelho et al., 2012).
Interestingly, a similar stepwise increase in the number of mutated
alleles was also observed for mutations in the gene LinJ30.1250
coding for a pyridoxal kinase detected in the two independent L.
major mutants (Coelho et al., 2012). These mutations were also
polyclonal, with at least two subpopulations differing in the number
of mutated alleles being found in a given population, and were im-
plicated in low-level resistance to miltefosine (Coelho et al., 2012).
Pyridoxal kinase is involved in the scavenging of vitamin B6 pre-
cursors but the mechanism by which it confers resistance to
miltefosine remains to be clariﬁed.
Genome-wide SNPs typing by next-generation sequencing rep-
resents a powerful approach for differentiating parasite strains among
natural populations and proved better than the more traditional
multi-locus microsatellite typing in informing on the population
history of closely related Leishmania strains (Downing et al., 2012).
Principal component analysis of genome-wide nucleotide varia-
tions between several L. donovani ﬁeld isolates from the Indian
subcontinent displaying varying levels of antimony susceptibility
supported the notion of multiple events of emergence of SSG re-
sistance that was previously reported (Laurent et al., 2007; Downing
et al., 2011, 2012). Evidence of adaptive evolution were also noted
for some genes that have a role in drug resistance (Downing et al.,
2011), with a high level of diversity detected in ATP-binding cas-
sette transporters (Castanys-Munoz et al., 2008; Leprohon et al.,
2009a), histone genes (Singh et al., 2007, 2010) and in the nucleo-
side transporter 1 (Vasudevan et al., 2001). While none of the SNPs
identiﬁed was universal to the SSG-resistant isolates (Downing et
al., 2011), a panel of ﬁve homozygous SNPs speciﬁcally detected in
SSG-resistant isolates proved useful for classifying the L. donovani
lines into eight multilocus sequencing typing haplotypes
(Vanaerschot et al., 2012). Interestingly, three haplotypes were sig-
niﬁcantly more associated with non-responsive or relapsing patients
compared to those that enjoyed deﬁnite cure (Vanaerschot et al.,
2012). These haplotypes gathered only few isolates however and
additional conﬁrmationwith a larger number of strains isolated from
patients with well-deﬁned SSG treatment outcomes are required
to truly assess the potential of these haplotypes in predicting SSG
treatment failure.
7. Natural extensions of NGS for studying the biology of
Leishmania
In addition to whole genome sequencing, NGS allows for cap-
turing the most signiﬁcant changes in gene expression by means
of RNA sequencing (RNA-seq), an approach that has several advan-
tages over other transcriptional proﬁling approaches like DNA
microarrays or serial analysis of gene expression (Nowrousian, 2010).
Although RNA-seq studies addressing drug resistance in Leishma-
nia still have to be reported, the approach has already proved
valuable in providing new knowledge about the heterogeneity of
spliced leader and polyadenylation sites for Leishmania mRNA, in
addition to allow the identiﬁcation of several new transcripts
(Rastrojo et al., 2013). A dual host-parasite RNA-seq experiment also
recently highlighted a potential transcriptional signature in primary
L. braziliensis cutaneous lesions that may predict the long-term de-
velopment of the mucosal form of the disease (Maretti-Mira et al.,
2012). RNA-seq also helped deciphering the role of iron, iron su-
peroxide dismutase and reactive oxygen species in the control of
amastigote differentiation in L. amazonensis (Mittra et al., 2013).
Owing to the unusual mechanisms of gene regulation in Leishma-
nia, one should be aware however that RNA-seq experiments in
Leishmania should greatly beneﬁt from companion proteomics pro-
ﬁling, as exempliﬁed by the analysis of the proteomic (by LC-MS/MS)
and transcriptomic (by RNA-seq) responses of L. donovani to purine
starvation that revealed that only a minority of changes detected
at the protein level tracked with changes at the mRNA level (Martin
et al., 2014).
Chromatin immunoprecipitation followed by hybridization on
DNAmicroarrays (ChIP-Chip) or NGS (ChIP-Seq) allow studying the
occupancy of DNA-binding proteins on the chromatin and the in-
terplay between chromatin structure and transcription. Eukaryotic
DNA is wrapped around nucleosomes composed of H2A, H2B, H3
and H4 histone proteins, with histone H1 contributing to larger order
structures. By substituting histone variants or through histonemodi-
ﬁcations, eukaryotes can regulate the availability of chromatin to
proteins involved in transcription. For example, acetylated histone
H3 is usually found at the 5′ end of transcription start sites and is
associated with increased transcription rates (Rando, 2007). While
the mechanism of transcription initiation in Leishmania is poorly
understood, ChIP-Chip and ChIP-Seq revealed that speciﬁc epigen-
etic marks are also present at putative transcriptional start and
termination sites in this parasite (Thomas et al., 2009; van Luenen
et al., 2012) and the related trypanosomatid Trypanosoma brucei
(Siegel et al., 2009). ChIP-Seq experiments have also been con-
ducted in our lab for mapping the precise location of the
trimethylation state of lysine 4 of histone H3 (3meH3K4) in the
context of drug resistance. This epigenetic mark is associated with
a loosening of the chromatin and active transcription and was found
to be enriched in the extrachromosomal element of drug-resistant
strains (Gazanion, unpublished results).
Finally, NGS provides a unique opportunity for developing in-
novative strategies to discover and validate different aspects of
Leishmania biology, including the identiﬁcation of themode of action
and resistance mechanisms of antimicrobials. We have recently de-
veloped a multi-copy suppressor screening strategy that combines
functional cloning and NGS for the detailed characterization of drugs’
mode of action and resistance determinants in Leishmania. The tech-
nique, termed Cos-seq, consists in generating genomic libraries in
multi-copy cosmids (i.e. Cl-Hygro) that are subsequently trans-
formed into drug sensitive parasites. The ﬁtness conferred by each
cosmid can then be analyzed by tracking the fate of individual
transformants grown as pools in liquid media in the presence of in-
cremental increases in drug pressure. By comparing the number of
sequence reads per gene between drug increments, one can observe
a gradual selection of genomic regions that bestow a selective ad-
vantage and a rapid clearance of those conferring increased
sensitivity. The approach was validated by identifying known drug
targets and resistance mechanisms for methotrexate and this tech-
nique was applied to a number of antileishmanial drugs and several
novel resistance determinants have been identiﬁed.
8. Conclusions
Whole genome sequencing has become affordable for large scale
studies in recent years and proved useful at detecting both known
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and new mechanisms of drug resistance in Leishmania. These also
highlighted the complexity of drug resistance which is often
polyclonal and involves several different co-existing genotypes in
a given population. This was observed for episome formation, where
stochastic ampliﬁcation of random loci in unstressed population can
favor adaptation; for gene deletion or duplication, with distinct break-
points occurring between parasites of a given population; for
aneuploidy, where the impressive variation in chromosome copy
numbers between species and strains renders the link with resis-
tance more diﬃcult to establish; and for SNPs, where different
mutations leading to resistance occur in a given population of par-
asite. This heterogeneity in both genotype and phenotype in resistant
populations may explain the diﬃculties when studying ﬁeld iso-
lates. Indeed, the polyclonal nature of resistance can lead to
mutations going unnoticed when analyzing parasite populations
because these will constitute rare events. In the situation where no
clones are dominant in the population, the analysis of several clones
and looking for similar events (e.g. different mutations targeting the
same gene between mutants) might thus be more revealing than
population analysis for the identiﬁcation of drug resistance mecha-
nisms and for characterizing the mechanisms implicated in their
genesis (e.g. to precisely map the breakpoints implicated in the de-
letion or the ampliﬁcation/duplication of a given locus). Finally,
additional studies will be required to understand more deeply the
clonal variety within resistant population and how it contributes
to either resistance or ﬁtness, as recently highlighted for popula-
tions of antibiotic-resistant bacteria (Lee et al., 2010; Vega et al.,
2012; El-Halfawy and Valvano, 2013).
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